Akeso and Summit's Experimental Drug Significantly Improves Lung Cancer Survival
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 hours ago
0mins
Source: Newsfilter
- Survival Rate Improvement: The experimental drug ivonescimab from Akeso and Summit Therapeutics demonstrated a 34% reduction in death risk in the Harmoni-6 Phase 3 trial conducted in China, extending the median survival of squamous non-small-cell lung cancer patients to 27.9 months, which is four months longer than standard treatment, highlighting its potential in difficult-to-treat populations.
- Global Research Outlook: While the trial was conducted exclusively in China, future global Phase 3 studies will further validate ivonescimab's efficacy across diverse populations, with experts noting that Chinese patients historically respond better to PD-1 and VEGF drugs, necessitating cautious interpretation of the data's applicability.
- Market Competition Landscape: The success of ivonescimab could position it as a successor to Merck's Keytruda; however, market analysts warn that its widespread adoption remains uncertain due to competition from emerging therapies, particularly antibody-drug conjugates that are gaining traction.
- Investment Surge: Licensing deals for PD-1 drugs reached $30 billion last year, nearly doubling the previous peak of $16 billion in 2017, reflecting strong market interest in new therapies, although ivonescimab's future requires more clinical data to support its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMMT
Wall Street analysts forecast SMMT stock price to rise
12 Analyst Rating
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 17.410
Low
18.00
Averages
42.49
High
131.90
Current: 17.410
Low
18.00
Averages
42.49
High
131.90
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chinese Biotech's Growing Impact on U.S. Stocks
- Emerging Risks from Chinese Innovation: Jefferies estimates that by 2025, about one-third of U.S. biotech licensing spending will be directed towards drugs developed in China, highlighting the rapid rise of Chinese biotech and posing potential threats to investment safety in U.S. firms.
- Clinical Trial Data Discrepancies: Summit Therapeutics' ivonescimab showed only a 33% reduction in progression-free survival for Western patients compared to 45% for Chinese patients in global phase 3 trials, raising concerns about FDA approval and increasing uncertainty for investors.
- Vulnerability of Big Pharma: While Merck has secured a $175 million deal with Kelun-Biotech, the risks associated with reliance on Chinese innovation remain, as they may face similar approval challenges as Summit, indicating potential fragility across the industry.
- Caution for Investors: Investors should scrutinize the source of a company's value before purchasing biotech stocks, as firms that develop their own drugs deserve higher valuations, while those relying on licensed products face additional risks that could lead to undervaluation.
See More
Impact of Chinese Biotech on U.S. Market Dynamics
- R&D Investment Risks: U.S. biotech firms' underinvestment in R&D may lead to increased reliance on Chinese innovation, with Jefferies estimating that about one-third of licensing spending will target Chinese drugs by 2025, indicating potential market risks for American companies.
- ivonescimab Clinical Trial Results: Summit Therapeutics' ivonescimab showed a 48% gain in progression-free survival in global phase 3 trials, but overall survival data did not achieve statistical significance, which could impact FDA approval decisions and highlights discrepancies between Chinese and Western patient data.
- Market Performance Decline: Summit's stock has dropped 35% over the past 12 months due to ivonescimab's survival shortfall and a broadly weak biotech market, underscoring the risks associated with reliance on external innovation.
- Future Outlook and Investment Strategy: As Chinese biotech rises, investors must carefully assess the source of a company's value, as those relying on external licenses may face higher risks, particularly in FDA approval processes, emphasizing the importance of in-house R&D capabilities.
See More
Ivonescimab Plus Chemotherapy Significantly Improves Survival Rates
- Significant Survival Improvement: In the HARMONi-6 clinical trial, patients receiving Ivonescimab plus chemotherapy had a 24-month overall survival rate of 64.7%, compared to 48.6% for those on Tislelizumab plus chemotherapy, indicating a 34% reduction in the risk of death and marking a crucial breakthrough in first-line NSCLC treatment.
- Statistical Significance: The trial reported a hazard ratio of 0.66 (95% CI: 0.50, 0.87; p=0.0017), demonstrating for the first time that Ivonescimab significantly improves overall survival compared to PD-1 inhibitors in first-line therapy, which could redefine treatment standards.
- Acceptable Safety Profile: Ivonescimab exhibited a safety profile consistent with previous trials, with treatment-related serious adverse events occurring in 41.4% of patients, compared to 34.3% for Tislelizumab, indicating its potential for clinical application.
- Future Outlook: Summit plans to hold a conference call on June 1, 2026, to discuss the latest data on Ivonescimab, further advancing its global clinical development and potentially offering new treatment options for patients.
See More
New Lung Cancer Drug ivonescimab Significantly Extends Survival
- Clinical Trial Results: The experimental drug ivonescimab from Akeso and Summit Therapeutics demonstrated a 34% reduction in death risk in late-stage trials, extending median survival by four months for patients with squamous non-small-cell lung cancer when combined with chemotherapy, indicating its potential in difficult-to-treat populations.
- Global Research Plans: The results from the Phase 3 trial conducted in China have garnered attention, and while a global Phase 3 study is ongoing, the applicability of the Chinese data to other populations remains uncertain, highlighting implications for future market dynamics.
- Market Reaction: Since Summit Therapeutics announced ivonescimab's superiority over Keytruda in a separate trial, its stock has surged nearly 600%, yet recent declines due to concerns over global efficacy reflect investor divisions regarding the drug's prospects.
- Safety Considerations: The trial revealed a bleeding incidence of nearly 25% in the ivonescimab group, double that of the control group, raising safety concerns despite fewer severe cases, which may impact market acceptance.
See More
Akeso and Summit's Experimental Drug Significantly Improves Lung Cancer Survival
- Survival Rate Improvement: The experimental drug ivonescimab from Akeso and Summit Therapeutics demonstrated a 34% reduction in death risk in the Harmoni-6 Phase 3 trial conducted in China, extending the median survival of squamous non-small-cell lung cancer patients to 27.9 months, which is four months longer than standard treatment, highlighting its potential in difficult-to-treat populations.
- Global Research Outlook: While the trial was conducted exclusively in China, future global Phase 3 studies will further validate ivonescimab's efficacy across diverse populations, with experts noting that Chinese patients historically respond better to PD-1 and VEGF drugs, necessitating cautious interpretation of the data's applicability.
- Market Competition Landscape: The success of ivonescimab could position it as a successor to Merck's Keytruda; however, market analysts warn that its widespread adoption remains uncertain due to competition from emerging therapies, particularly antibody-drug conjugates that are gaining traction.
- Investment Surge: Licensing deals for PD-1 drugs reached $30 billion last year, nearly doubling the previous peak of $16 billion in 2017, reflecting strong market interest in new therapies, although ivonescimab's future requires more clinical data to support its market position.
See More
Ivonescimab Shows Promising Results in mCRC Clinical Development
- Clinical Trial Results: In the recent AK112-206 trial, patients receiving ivonescimab combined with mFOLFOX6 chemotherapy achieved an objective response rate (ORR) of 70.8%, indicating the drug's potential in treating metastatic colorectal cancer (mCRC) and surpassing historical benchmarks for standard therapies.
- Tolerability and Safety: The safety profile of ivonescimab aligns with historical data, with 20.4% of patients experiencing serious treatment-related adverse events (TRAEs) but no new safety signals observed, suggesting good tolerability and suitability for further development.
- Durability of Efficacy: In the ivonescimab 20 mg/kg group, the duration of response landmark estimate at 9 months was 79.1%, compared to 41.5% in the 10 mg/kg group, indicating that the higher dose may offer better long-term survival prospects for patients.
- Future Research Directions: Summit is conducting the HARMONi-GI3 trial to evaluate the combined efficacy of ivonescimab with mFOLFOX6 chemotherapy, which is expected to provide new treatment options for patients with metastatic colorectal cancer and further advance the clinical development of this drug.
See More
Chinese Biotech's Growing Impact on U.S. Stocks
- Emerging Risks from Chinese Innovation: Jefferies estimates that by 2025, about one-third of U.S. biotech licensing spending will be directed towards drugs developed in China, highlighting the rapid rise of Chinese biotech and posing potential threats to investment safety in U.S. firms.
- Clinical Trial Data Discrepancies: Summit Therapeutics' ivonescimab showed only a 33% reduction in progression-free survival for Western patients compared to 45% for Chinese patients in global phase 3 trials, raising concerns about FDA approval and increasing uncertainty for investors.
- Vulnerability of Big Pharma: While Merck has secured a $175 million deal with Kelun-Biotech, the risks associated with reliance on Chinese innovation remain, as they may face similar approval challenges as Summit, indicating potential fragility across the industry.
- Caution for Investors: Investors should scrutinize the source of a company's value before purchasing biotech stocks, as firms that develop their own drugs deserve higher valuations, while those relying on licensed products face additional risks that could lead to undervaluation.
See More
Impact of Chinese Biotech on U.S. Market Dynamics
- R&D Investment Risks: U.S. biotech firms' underinvestment in R&D may lead to increased reliance on Chinese innovation, with Jefferies estimating that about one-third of licensing spending will target Chinese drugs by 2025, indicating potential market risks for American companies.
- ivonescimab Clinical Trial Results: Summit Therapeutics' ivonescimab showed a 48% gain in progression-free survival in global phase 3 trials, but overall survival data did not achieve statistical significance, which could impact FDA approval decisions and highlights discrepancies between Chinese and Western patient data.
- Market Performance Decline: Summit's stock has dropped 35% over the past 12 months due to ivonescimab's survival shortfall and a broadly weak biotech market, underscoring the risks associated with reliance on external innovation.
- Future Outlook and Investment Strategy: As Chinese biotech rises, investors must carefully assess the source of a company's value, as those relying on external licenses may face higher risks, particularly in FDA approval processes, emphasizing the importance of in-house R&D capabilities.
See More
Ivonescimab Plus Chemotherapy Significantly Improves Survival Rates
- Significant Survival Improvement: In the HARMONi-6 clinical trial, patients receiving Ivonescimab plus chemotherapy had a 24-month overall survival rate of 64.7%, compared to 48.6% for those on Tislelizumab plus chemotherapy, indicating a 34% reduction in the risk of death and marking a crucial breakthrough in first-line NSCLC treatment.
- Statistical Significance: The trial reported a hazard ratio of 0.66 (95% CI: 0.50, 0.87; p=0.0017), demonstrating for the first time that Ivonescimab significantly improves overall survival compared to PD-1 inhibitors in first-line therapy, which could redefine treatment standards.
- Acceptable Safety Profile: Ivonescimab exhibited a safety profile consistent with previous trials, with treatment-related serious adverse events occurring in 41.4% of patients, compared to 34.3% for Tislelizumab, indicating its potential for clinical application.
- Future Outlook: Summit plans to hold a conference call on June 1, 2026, to discuss the latest data on Ivonescimab, further advancing its global clinical development and potentially offering new treatment options for patients.
See More
New Lung Cancer Drug ivonescimab Significantly Extends Survival
- Clinical Trial Results: The experimental drug ivonescimab from Akeso and Summit Therapeutics demonstrated a 34% reduction in death risk in late-stage trials, extending median survival by four months for patients with squamous non-small-cell lung cancer when combined with chemotherapy, indicating its potential in difficult-to-treat populations.
- Global Research Plans: The results from the Phase 3 trial conducted in China have garnered attention, and while a global Phase 3 study is ongoing, the applicability of the Chinese data to other populations remains uncertain, highlighting implications for future market dynamics.
- Market Reaction: Since Summit Therapeutics announced ivonescimab's superiority over Keytruda in a separate trial, its stock has surged nearly 600%, yet recent declines due to concerns over global efficacy reflect investor divisions regarding the drug's prospects.
- Safety Considerations: The trial revealed a bleeding incidence of nearly 25% in the ivonescimab group, double that of the control group, raising safety concerns despite fewer severe cases, which may impact market acceptance.
See More
Akeso and Summit's Experimental Drug Significantly Improves Lung Cancer Survival
- Survival Rate Improvement: The experimental drug ivonescimab from Akeso and Summit Therapeutics demonstrated a 34% reduction in death risk in the Harmoni-6 Phase 3 trial conducted in China, extending the median survival of squamous non-small-cell lung cancer patients to 27.9 months, which is four months longer than standard treatment, highlighting its potential in difficult-to-treat populations.
- Global Research Outlook: While the trial was conducted exclusively in China, future global Phase 3 studies will further validate ivonescimab's efficacy across diverse populations, with experts noting that Chinese patients historically respond better to PD-1 and VEGF drugs, necessitating cautious interpretation of the data's applicability.
- Market Competition Landscape: The success of ivonescimab could position it as a successor to Merck's Keytruda; however, market analysts warn that its widespread adoption remains uncertain due to competition from emerging therapies, particularly antibody-drug conjugates that are gaining traction.
- Investment Surge: Licensing deals for PD-1 drugs reached $30 billion last year, nearly doubling the previous peak of $16 billion in 2017, reflecting strong market interest in new therapies, although ivonescimab's future requires more clinical data to support its market position.
See More
Ivonescimab Shows Promising Results in mCRC Clinical Development
- Clinical Trial Results: In the recent AK112-206 trial, patients receiving ivonescimab combined with mFOLFOX6 chemotherapy achieved an objective response rate (ORR) of 70.8%, indicating the drug's potential in treating metastatic colorectal cancer (mCRC) and surpassing historical benchmarks for standard therapies.
- Tolerability and Safety: The safety profile of ivonescimab aligns with historical data, with 20.4% of patients experiencing serious treatment-related adverse events (TRAEs) but no new safety signals observed, suggesting good tolerability and suitability for further development.
- Durability of Efficacy: In the ivonescimab 20 mg/kg group, the duration of response landmark estimate at 9 months was 79.1%, compared to 41.5% in the 10 mg/kg group, indicating that the higher dose may offer better long-term survival prospects for patients.
- Future Research Directions: Summit is conducting the HARMONi-GI3 trial to evaluate the combined efficacy of ivonescimab with mFOLFOX6 chemotherapy, which is expected to provide new treatment options for patients with metastatic colorectal cancer and further advance the clinical development of this drug.
See More
